GNRH1 and ovarian hyperstimulation syndrome: An update of the Cochrane review has shown no evidence of a difference in LBRs between the GnRH-ant and the long GnRH-a protocols; however, the GnRH-ant treatment was associated with a lower incidence of any grade of ovarian hyperstimulation syndrome in comparison to the GnRH-a protocol [22].